Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
23 5월 2008 - 2:30AM
PR Newswire (US)
Presentation Will be Webcast Live and Archived on Company's Website
ROCKVILLE, Md., May 22 /PRNewswire-FirstCall/ -- Vanda
Pharmaceuticals Inc. (NASDAQ:VNDA), a biopharmaceutical company
focused on the development and commercialization of clinical-stage
product candidates for central nervous system disorders, today
announced that Mihael H. Polymeropoulos, M.D., Vanda President and
CEO will deliver a corporate presentation on Wednesday, May 28,
2008, at 9:00 a.m. Eastern Time. The presentation will take place
as part of the FBR Capital Markets 12th Annual Spring Investor
Conference at the Grand Hyatt, New York, New York. Dr.
Polymeropoulos' remarks will be available live on the Vanda
Website, where it also will be archived for 30 days. To access the
presentation, log on to http://www.vandapharma.com/ and click on
the Presentations option in the Investor Relations section. Please
connect to the website several minutes prior to the start of the
live presentation. About Vanda Pharmaceuticals Inc. Vanda
Pharmaceuticals Inc. (NASDAQ:VNDA) is a biopharmaceutical company
focused on the development and commercialization of clinical-stage
product candidates for central nervous system disorders. The
company has three product candidates. Vanda's lead product
candidate, Fanapta(TM) (iloperidone), for which Vanda has recently
submitted an NDA to the FDA, is a compound for the treatment of
schizophrenia. Vanda's second product candidate, tasimelteon
(VEC-162), is a compound for the treatment of sleep and mood
disorders, which is currently in Phase III for chronic primary
insomnia. Vanda's third product candidate, VSF-173, is a compound
for the treatment of excessive sleepiness in Phase II. For more on
Vanda Pharmaceuticals Inc., please visit
http://www.vandapharma.com/. DATASOURCE: Vanda Pharmaceuticals Inc.
CONTACT: Steven Shallcross, Chief Financial Officer of Vanda
Pharmaceuticals Inc., +1-240-599-4500, Web site:
http://www.vandapharma.com/
Copyright
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Vanda Pharmaceuticals (NASDAQ:VNDA)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024